Get the Stockscreener App
33.11
2.13%
-0.72
After Hours:
33.34
0.23
+0.69%
Legend Biotech Corp Adr stock is traded at $33.11, with a volume of 1.72M.
It is down -2.13% in the last 24 hours and down -10.49% over the past month.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
See More
Previous Close:
$33.83
Open:
$34.09
24h Volume:
1.72M
Relative Volume:
1.28
Market Cap:
$6.11B
Revenue:
$520.18M
Net Income/Loss:
$-348.13M
P/E Ratio:
-17.24
EPS:
-1.92
Net Cash Flow:
$-176.18M
1W Performance:
-8.23%
1M Performance:
-10.49%
6M Performance:
-13.42%
1Y Performance:
-34.72%
1-Day Range:
$32.70
$34.45
1-Week Range:
$32.70
$36.38
52-Week Range:
$27.34
$52.31
Legend Biotech Corp Adr Stock (LEGN) Company Profile
Name
Legend Biotech Corp Adr
Sector
Industry
Phone
-
Address
-
Compare LEGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
33.11 | 6.18B | 520.18M | -348.13M | -176.18M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Jun-17-24 | Initiated | Truist | Buy |
| May-24-24 | Reiterated | H.C. Wainwright | Buy |
| May-23-24 | Initiated | Deutsche Bank | Buy |
| Apr-17-24 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Apr-03-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-24 | Initiated | Raymond James | Outperform |
| Dec-19-23 | Initiated | Scotiabank | Sector Perform |
| Nov-06-23 | Initiated | Goldman | Buy |
| May-25-23 | Initiated | William Blair | Mkt Perform |
| May-22-23 | Initiated | Daiwa Securities | Buy |
| Mar-29-23 | Initiated | H.C. Wainwright | Buy |
| Mar-24-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-22 | Initiated | UBS | Buy |
| Nov-02-22 | Initiated | Evercore ISI | Outperform |
| Nov-01-22 | Initiated | Cowen | Outperform |
| Oct-31-22 | Initiated | Guggenheim | Neutral |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Mar-15-22 | Initiated | Barclays | Overweight |
| Jan-31-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-21-21 | Initiated | Piper Sandler | Overweight |
| May-18-21 | Initiated | BTIG Research | Buy |
| Jul-01-20 | Initiated | JP Morgan | Overweight |
| Jul-01-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Morgan Stanley | Overweight |
View All
Legend Biotech Corp Adr Stock (LEGN) Latest News
Alliancebernstein L.P. Purchases 32,101 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech stock rating reiterated at Outperform by RBC Capital - Investing.com
Advisors Asset Management Inc. Purchases 13,070 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech Corporation Sponsored ADR $LEGN Stake Decreased by Cinctive Capital Management LP - MarketBeat
Nomura Holdings Inc. Purchases New Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech at Morgan Stanley Conference: CARVYKTI’s Global Impact - Investing.com
Legend Biotech (NASDAQ:LEGN) Shares Up 5.4%Here's Why - MarketBeat
Legend Biotech Mulling 2nd Listing in HK, Singapore, or London: Wire - AASTOCKS.com
Northern Trust Corp Has $9.73 Million Stake in Legend Biotech Corporation Sponsored ADR $LEGN - Defense World
OMERS ADMINISTRATION Corp Buys Shares of 40,400 Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Cantor Fitzgerald Expects Weaker Earnings for Legend Biotech - MarketBeat
Legend Biotech’s SWOT analysis: carvykti success drives stock potential amid challenges - Investing.com India
Tema Etfs LLC Purchases 40,646 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Nuveen LLC Purchases Shares of 170,186 Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Brokers Issue Forecasts for Legend Biotech FY2025 Earnings - Defense World
Legend Biotech (NASDAQ:LEGN) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World
Resolute Capital Asset Partners LLC Buys New Stake in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
170,186 Shares in Legend Biotech Corporation Sponsored ADR $LEGN Purchased by Nuveen LLC - Defense World
Legend Biotech (NASDAQ:LEGN) Price Target Raised to $78.00 at JPMorgan Chase & Co. - Defense World
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Receives $72.38 Average PT from Brokerages - Defense World
PNC Financial Services Group Inc. Buys 3,238 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - Defense World
Swiss National Bank Has $5.53 Million Holdings in National Storage Affiliates Trust $NSA - Defense World
Legend Biotech Corporation Sponsored ADR $LEGN Stock Holdings Boosted by Swiss National Bank - Defense World
US Bancorp DE Lowers Position in Legend Biotech Corporation Sponsored ADR $LEGN - Defense World
Legend Biotech names Carlos Santos as new CFO - Investing.com
Legend Biotech’s SWOT analysis: carvykti drives growth as stock faces competition - Investing.com
Legend Biotech’s SWOT analysis: carvykti drives growth as stock faces competition By Investing.com - Investing.com South Africa
Company News for Aug 12, 2025 - NewsBreak: Local News & Alerts
Legend Biotech (NASDAQ:LEGN) Price Target Raised to $83.00 at Morgan Stanley - Defense World
Legend Biotech (NASDAQ:LEGN) Receives Outperform Rating from Royal Bank Of Canada - Defense World
Legend Biotech stock price target raised to $77 by RBC Capital - Investing.com South Africa
Earnings call transcript: Legend Biotech Q2 2025 reveals strong revenue growth - Investing.com
Earnings call transcript: Legend Biotech Q2 2025 reveals strong revenue growth By Investing.com - Investing.com South Africa
Legend Biotech Q2 2025 slides: CARVYKTI sales surge 136%, adjusted profit achieved - Investing.com India
XTX Topco Ltd Takes $307,000 Position in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) - Defense World
Legend Biotech on Track for Record Losing Streak — Data Talk - Morningstar
Cantor Fitzgerald Estimates Legend Biotech FY2025 Earnings - Defense World
Brokerages Set Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Price Target at $73.33 - Defense World
Bank of New York Mellon Corp Has $4.55 Million Stake in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) - Defense World
HC Wainwright Forecasts Legend Biotech Q2 Earnings - Defense World
Legend Biotech’s (LEGN) Buy Rating Reiterated at HC Wainwright - Defense World
Q1 EPS Estimates for Legend Biotech Raised by HC Wainwright - Defense World
Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains? - Yahoo Finance
Legend Biotech’s SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com India
Legend Biotech’s SWOT analysis: stock poised for growth amid challenges - Investing.com
H.C. Wainwright reiterates Buy rating on Legend Biotech stock after strong CARVYKTI sales - Investing.com India
Goldman Sachs reiterates buy rating on Legend Biotech stock after strong Carvykti sales - Investing.com India
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Shares Acquired by GAMMA Investing LLC - Defense World
Legend Biotech stock price target lowered to $54 at UBS on growth concerns - Investing.com
Legend Biotech stock maintains Buy rating as FDA eases CARVYKTI restrictions - Investing.com
Bristol Myers, Gilead, J&J, Novartis win favorable FDA label updates for cell therapies - Seeking Alpha
Legend Biotech Corp Adr Stock (LEGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):